PDS Biotechnology, a clinical stage immunotherapy company, has announced positive results from preclinical testing conducted at the University of Kentucky College of Medicine of its COVID-19 vaccine candidate, PDS0203.
Cats can contract an almost always fatal disease that’s caused by a coronavirus that infects only felines. Now preliminary research suggests that two experimental drugs that can cure that disease in cats, called feline infectious peritonitis, might help treat people infected with SARS-CoV-2, the coronavirus behind the pandemic.
The race to find a cure for SARS-CoV-2, the virus that causes COVID-19, is heating up around the world as countries battle to see which one can produce a winner first.
A new study from the Regenerative Bioscience Center at the University of Georgia is the first to suggest that COVID-19 does not directly damage taste bud cells.
The coronavirus that causes COVID-19 infects cells by plugging into a receptor on their surface. Now, by crafting a "decoy" of that receptor, scientists aim to foil the virus's attack.
When Chinese researchers shared the genetic sequence of the new coronavirus on Jan. 10, University of Texas researchers were able to quickly map the virus and inject it with previously-discovered mutations, allowing the researchers to freeze a key protein in a way that would become essential for creating a vaccine.
The National Institutes of Health has awarded a grant of $1.2 million to the Mouse Biology Program at the University of California, Davis, to create mice that are susceptible to the COVID-19 virus, and to distribute them to researchers.
More than 125 potential vaccines are in development some seven months after the world first learned of the coronavirus. We can thank animal research for that.
The investigational vaccine known as mRNA-1273 protected mice from infection with SARS-CoV-2, the virus that causes COVID-19, according to research published today in Nature.
After conducting phase III trials of REGN-COV-2, a two-antibody cocktail to treat and prevent COVID-19, Regeneron Pharmaceuticals said the cocktail was able to “almost completely block establishment of virus infection” in rhesus macaques and hamsters.
Novavax, the little-known Maryland company that received a $1.6 billion deal from the federal government for its experimental coronavirus vaccine, announced encouraging results in two preliminary studies on Tuesday.
NIH and Moderna announced the start of a multi-site, Phase 3 clinical trial of a candidate vaccine for COVID-19.
Moderna has received an additional $472 million from the U.S. government’s Biomedical Advanced Research and Development Authority to support late-stage clinical development of Moderna’s vaccine candidate.
The COVID-19 vaccine candidate made by the U.S. biotech company Moderna and developed in collaboration with the National Institutes of Health starts its final phase of testing Monday.
An experimental messenger RNA (mRNA)-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits protective immune responses in mice and non-human primates. Two injections of the vaccine were sufficient to induce robust immunity, completely preventing SARS-CoV-2 infection in mice.
The vaccine candidate repRNA-CoV2S elicited both antibody and T cell responses after just two injections in mice and macaques.
While the latest research suggests that antibodies against Covid-19 could be lost in just three months, a new hope has appeared on the horizon: the enigmatic T cell.
University of Washington researchers, in partnership with a Seattle biotech company, say they have developed a promising candidate for vaccination against the virus that causes COVID-19.
A replicating RNA vaccine, formulated with a lipid-based nanoparticle emulsion that goes by the acronym LION, produces antibodies against the COVID-19 coronavirus in mice and primates with a single immunization.
A candidate vaccine against COVID-19 developed by the federal government and Moderna appears to be safe and to trigger an immune response, according to data released Tuesday from an early phase trial.
Data suggest antiviral can cut death risk in people, and stop virus growth in cells and mice.
Altimmune, Inc., a clinical-stage biopharmaceutical company, has announced positive results from the preclinical studies conducted in mice at the University of Alabama at Birmingham of its intranasal COVID-19 vaccine candidate, AdCOVID.
Thailand is starting the clinical stage for its own Covid-19 vaccine after both monkeys and mice generated satisfactory antibodies against the virus following injections, according to scientists in the study.
Researchers at Providence St. Joseph have submitted their research data to the FDA and are awaiting approval to move into phase one of a vaccine trial.
A new study found that remdesivir potently inhibited SARS-CoV-2, the virus which causes COVID-19, in human lung cell cultures and that it improved lung function in mice infected with the virus.
